Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Unit, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Intern Med J. 2020 Jul;50(7):798-804. doi: 10.1111/imj.14889.
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.
由新型冠状病毒 SARS-CoV-2 引起的 COVID-19 大流行已经成为一项公共卫生紧急事件,对全球的医疗保健系统构成了挑战。在少数患者中,SARS-CoV-2 表现为严重急性呼吸道疾病,目前关于接受免疫抑制治疗的炎症性肠病患者 COVID-19 的毒力的数据还不足够。这篇综述旨在总结目前的文献,并就澳大利亚背景下 COVID-19 大流行期间炎症性肠病患者的管理提供指导。